

Figure S1. *In vivo* efficacy of rRp450 combined with VEGF blockade. Mice bearing A673 tumors received received two intratumoral injections of saline (control) or rRp450 at 1×10^7 pfu on days 0 and 2 and the indicated antibody (IgG, control; Bev, bevacizumab; r84, which blocks mVEGF and hVEGF-VEGFR2 binding. Tumors were followed for growth and tallied by their best response (PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response; n=7-8).